Index of /template_files/1402/PR

	Name	Last modified	Size	Description
	Parent Directory		-
	2018.09.12 Virpax Reports Pre-IND Guidance From FDA for DSF100.pdf	22-Feb-2023 10:37	44K
	2018.12.27 Virpax announces Successful PIND Meeting for LBL100.pdf	22-Feb-2023 10:37	164K
	2019.04.16 Virpax Licenses MET Intranasal Formulation from Nanomerics.pdf	22-Feb-2023 10:37	159K
	2019.04.24 Virpax to Present at ThinkEquity Conference.pdf	22-Feb-2023 10:37	144K
	2019.06.03 Virpax selected for Two Presentations at the 2019 MHSRS.pdf	22-Feb-2023 10:37	129K
	2019.08.06 Virpax to Present at 2019 MHSRS.pdf	22-Feb-2023 10:37	86K
	2019.09.10 VIRPAX BOD Appointment Final.pdf	22-Feb-2023 10:37	153K
	2019.09.17 VIRPAX Appointment Gerald Bruce Final.pdf	22-Feb-2023 10:37	151K
	2020.01.14 Virpax to Develop Its MET Intranasal Enkephalin Formulation 01.14.2020.pdf	22-Feb-2023 10:37	159K
	2020.02.05 Virpax Pharmaceuticals SOMSA DSF100 and NES100 Final.pdf	22-Feb-2023 10:37	177K
	2020.03.02 PIND NES100 Virpax Pharmaceuticals Final.pdf	22-Feb-2023 10:37	157K
	2020.03.19 PIND OSF200 Virpax Pharmaceuticals.pdf	22-Feb-2023 10:37	191K
	2020.04.28 VIRPAX New Board Member_Jacob.pdf	22-Feb-2023 10:37	193K
	2020.06.02 Virpax Pharmaceuticals Announces Appt of Chris Chipman CFO.pdf	22-Feb-2023 10:37	171K
	2020.07.09 Vanila Singh Elected to Virpax Pharmaceuticals BOD.pdf	22-Feb-2023 10:37	186K
	2020.08.24 Virpax Pharma to Develop MMS019.pdf	22-Feb-2023 10:37	159K
	2020.08.31 NES100 Virpax Pharmaceuticals Enters into CRADA for NES100.pdf	22-Feb-2023 10:37	157K
	2020.12.08 MMS019 inhibits SARS-COV-2.pdf	22-Feb-2023 10:37	157K
	2021.02.16 Virpax Pharmaceuticals Announces Pricing of Initial Public Offering.pdf	22-Feb-2023 10:37	203K
	2021.02.19 Virpax Pharmaceuticals Announces Closing of Initial Public Offering.pdf	22-Feb-2023 10:37	176K
	2021.02.23 Virpax_Envelta - IND Enabling Studies Annoucement.pdf	22-Feb-2023 10:37	200K
	2021.03.02 Virpax Pharmaceuticals Announces Newly Issued Patent for Probudur.pdf	22-Feb-2023 10:37	129K
	2021.03.10 Virpax to Initiate IND Enabling Studies Epoladerm.pdf	22-Feb-2023 10:37	205K
	2021.03.22 Virpax to Initiate IND Enabling Studies Probudur.pdf	22-Feb-2023 10:37	209K
	2021.04.05 Virpax_Probudur demonstrates minimal local nerve toxicity.pdf	22-Feb-2023 10:37	192K
	2021.08.17 Virpax Receives FDA Response and Guidance on MMS019.pdf	22-Feb-2023 10:37	153K
	2021.10.01 Virpax to Present at the NobleCon Online Pain Management Investor Forum.pdf	22-Feb-2023 10:37	142K
	2021.10.06 Virpax Signs Agreement to Initiate IND Studies for AnQlar1.pdf	22-Feb-2023 10:37	229K
	2021.12.08 VRPX Reports Successful Results of Tox Pharmacokinetic Studies Epoladerm.pdf	22-Feb-2023 10:37	165K
	2021.12.20 VRPX Announces Clinical Trial Site in Canada for FIH Study of Epoladerm.pdf	22-Feb-2023 10:37	194K
	2021.12.28 Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio.pdf	22-Feb-2023 10:37	156K
	2022.01.04 Virpax to Present at H.C. Wainwright BioConnect Virtual Conference Final.pdf	22-Feb-2023 10:37	175K
	Envelta IND enabling studies - expanded indications Final 06.21.2021 w.logo.pdf	22-Feb-2023 10:37	165K
	LD Micro Conference_Virpax Press Release Final 06.02.2021 Logo.pdf	22-Feb-2023 10:37	151K
	Torreya_Virpax Press Release Final w.logo 04.22.2021.pdf	22-Feb-2023 10:37	144K
	VRPX Announces Closing of $40 Million Public Offering of Common Stock w. logo .pdf	22-Feb-2023 10:37	163K
	VRPX Follow On Press Release Pricing 4834-8259-7114 Final 09.14.2021 w. logo.pdf	22-Feb-2023 10:37	168K
	Virpax Announces MMS019 Manufacturing and Supply Agreement 08.26.2021 w.logo.pdf	22-Feb-2023 10:37	151K
	Virpax Announces Poster Presentation for Envelta at PAINWeek 2021.pdf	22-Feb-2023 10:37	151K
	Virpax Announces Successful Completion of Its Dermal Safety Trials for Epoladerm Final.pdf	22-Feb-2023 10:37	165K
	Virpax Continues to Advance Envelta Development Under CRADA 11.10.2021 Final w.logo.pdf	22-Feb-2023 10:37	157K
	Virpax Earnings Release 2nd Qtr Final 08.10.2021.pdf	22-Feb-2023 10:37	308K
	Virpax Earnings Release Final 05-18-21.pdf	22-Feb-2023 10:37	289K
	Virpax Pharmaceuticals Reports 2021 Third Quarter Final 11.15.2021 w logo.pdf	22-Feb-2023 10:37	345K
	Virpax Provides Progress Update on Product Candidates Final 07.07.2021.pdf	22-Feb-2023 10:37	147K
	VirpaxReportsFavorablePreclinicalSafetyDataforEnvelta.pdf	22-Feb-2023 10:37	190K
	Virpax Strengthens Board of Directors 07.30.21 Final w Logo.pdf	22-Feb-2023 10:37	187K
	Virpax_MMS019 InVivo Data 04.19.2021 Final w logo.pdf	22-Feb-2023 10:37	213K
	Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy 09.20.2021 w logo.pdf	22-Feb-2023 10:37	145K